Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.

Tang A, Rabasa-Lhoret R, Castel H, Wartelle-Bladou C, Gilbert G, Massicotte-Tisluck K, Chartrand G, Olivié D, Julien AS, de Guise J, Soulez G, Chiasson JL

Diabetes care26 Mar 2015Cited by 104 (Europe PMC)

PMID25813773DOI10.2337/dc14-2548PepBankPUB-25813773

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the change in liver fat fraction with liraglutide did not differ significantly from the change with insulin glargine.
In plain wordsIn adults with type 2 diabetes, liver fat change did not differ significantly between liraglutide and insulin glargine; liraglutide alone did not change it.
Peptide
Liraglutide
Outcome
No significant changeLiver fat fraction versus insulin glargine
Study
n = 35
Comparator
Insulin glargine
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377306
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the improvement in glycemic control with liraglutide was not significantly different from insulin glargine.
In plain wordsIn adults with type 2 diabetes, blood sugar control improved about as much with liraglutide as with insulin glargine; the difference was not significant.
Peptide
Liraglutide
Outcome
No significant changeGlycemic control versus insulin glargine
Study
n = 35
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377307
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes inadequately controlled on oral agents, 12 weeks of liraglutide significantly improved glycated hemoglobin from 7.6% to 6.7%.
In plain wordsIn adults with type 2 diabetes, blood sugar control (glycated hemoglobin) improved during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseGlycated hemoglobin change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
HbA1c before
7.6%
liraglutide
HbA1c after
6.7%
liraglutide
Source sentences
Summary
Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7.6% to 6.7% [59.8 to 50.2 mmol/mol], P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377301
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide did not change liver proton density fat fraction measured by MRS (P = 0.80).
In plain wordsIn adults with type 2 diabetes, liraglutide did not change liver fat measured by MR spectroscopy.
Peptide
Liraglutide
Outcome
No significant changeLiver fat by MRS-PDFF
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39).
2 context sentences(design, population, supporting numbers)
Summary · context
The liver proton density fat fraction (PDFF) was measured by MRS.
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377302
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide did not change liver mean MRI-PDFF (P = 0.15).
In plain wordsIn adults with type 2 diabetes, liraglutide did not change liver fat measured by MRI.
Peptide
Liraglutide
Outcome
No significant changeLiver mean MRI-PDFF
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39).
2 context sentences(design, population, supporting numbers)
Summary · context
The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI.
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377303
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide did not change liver volume (P = 0.30).
In plain wordsIn adults with type 2 diabetes, liraglutide did not change liver volume.
Peptide
Liraglutide
Outcome
No significant changeLiver volume
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39).
2 context sentences(design, population, supporting numbers)
Summary · context
The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI.
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377304
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide did not change the total liver fat index (P = 0.39).
In plain wordsIn adults with type 2 diabetes, liraglutide did not change the total liver fat index.
Peptide
Liraglutide
Outcome
No significant changeTotal liver fat index
Study
n: not reported in source
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39).
2 context sentences(design, population, supporting numbers)
Summary · context
The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI.
Summary · context
Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks.
Report a problemFND-2581377305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01399645

Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Centre hospitalier de l'Université de Montréal (CHUM)n = 35May 2011 to Jun 2014

Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis · Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 27 Aug 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.